Emerging biotech companies in England is responding with this step Scancell in the open market traded according to the corresponding interest by investors. CEO Richard Goodfellow added: after various meetings in the recent past and our recent successes in raising funds, our company could arouse great interest among German investors. A listing on the Frankfurt Stock Exchange offers these investors the opportunity to trade the Scancell share in addition to our London listing on the Frankfurt Stock Exchange. We assume that we motivate also German small investors to the regular trade with the admission to trading in Frankfurt. It remains our aim to increase the liquidity of our shares and to create a broad base of investors, to achieve more presence in the European investors. The coming year will be crucial for Scancell; We currently wait SCIB1 for the results of clinical trials with the vaccine in the treatment of malignant melanoma and want our modes Tope platform further develop.” The British company developed novel immune therapies for treating cancer. This method should otherwise not more kurierbare cancer into a chronic disease”are convicted that medically appropriate can be kept in check.
Scancells lead product, the ImmunoBody SCIB1, is located in the phase I/II of clinical trials. First interim results were positive. Melanie Holtmann / Dr. Reuter investor relations